Omkar Spl.Chem.

- Promoters have taken an unsecured interest-free loan of Rs. 60 crores to the company, which is part of the total loan of Rs. 218 crores as of March 31, 2017. - External borrowings have reduced from Rs. 185 crores to Rs. 158 crores. - Management is not currently focused on raising new equity; recent shares pledged have been sold, and no further share sales are planned. - There is an expectation to sanction new working capital loans from banks now that the demerger is complete. - Promoters have expressed commitment to increase their shareholding but have not detailed the means. - Long-term loans are being repaid quarterly, with plans to reduce them by Rs. 10-15 crores over time. - No mention of immediate large-scale future fundraising via debt or equity; focus is on managing existing loans and internal resources.

- The company is focusing on contract manufacturing (job working) by utilizing external facilities to avoid heavy CAPEX investments. - They have already engaged about five different external facilities for job working to enhance flexibility and reduce capital expenditure. - Future growth will be supported by this model rather than in-house expansion, thus limiting CAPEX needs. - Long-term loans have increased to fund some CAPEX, but the company is actively repaying these loans quarterly. - No explicit mention of large new CAPEX or strategic investments, with emphasis on improved working capital management and efficient asset utilization.

- Company is targeting a modest growth rate of 15% to 17% in the current year (FY18). - Expect continued strong growth momentum across all business segments. - Specialty and higher-margin products, including advanced intermediates, are key focus areas driving growth. - New product lines catering to FMCG, perfumes, fragrances, food & beverages, and nutrients expected to significantly contribute. - FMCG-related products revenue expected to grow from 10-12% last year to about 25% this year, potentially doubling. - Export contribution is increasing and expected to continue growing. - Improved working capital cycle and operational efficiencies support smoother growth. - Expansion into contract manufacturing/job working model to enable growth without heavy CAPEX.

- Omkar Specialty Chemicals targets a modest revenue growth of 15% to 17% in the current year (FY18). - Margins are expected to be maintained, with management being "very, very fairly confident" of holding them despite pricing pressures. - Focus on higher margin specialty products and innovative product lines (perfumes, fragrances, FMCG chemicals) is expected to drive growth and profitability. - Working capital improvements and shift towards contract manufacturing/job working will enhance operational efficiency and reduce capital expenditure, positively impacting profits. - EBITDA margin improved to 16.6% in FY17 and expected to sustain or improve with higher operating efficiencies. - Expansion in FMCG division expected to grow from 10-12% of topline last year to about 25% this year, indicating diversification in revenue sources. - Management emphasizes continuing product and customer selectivity to sustain growth and profit margins.

The provided transcript from Omkar Specialty Chemicals Limited’s May 24, 2017 call does not explicitly mention the current or expected order book or pending orders. However, insights related to growth expectations and business trends include: - The company is targeting growth of about 15% to 17% for the current year. - They are focusing on specialty and higher-end intermediates, which are expected to drive growth. - Expansion in FMCG-related products is expected to increase from about 10-12% of topline last year to approximately 25%. - Capacity utilization at Lasa (a subsidiary or related entity) is around 75%. - Working capital improvements and selective customer credit terms aim to support smoother order fulfillment and growth. For detailed order book or pending orders status, the document does not provide explicit figures or projections.